Compare MMSI & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMSI | AMRX |
|---|---|---|
| Founded | 1987 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.0B |
| IPO Year | 1996 | 2018 |
| Metric | MMSI | AMRX |
|---|---|---|
| Price | $68.23 | $12.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $103.56 | $14.75 |
| AVG Volume (30 Days) | 740.9K | ★ 1.9M |
| Earning Date | 04-23-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.93 | ★ 157.89 |
| EPS | ★ 2.13 | 0.22 |
| Revenue | ★ $1,515,906,000.00 | N/A |
| Revenue This Year | $8.78 | $6.40 |
| Revenue Next Year | $5.70 | $6.54 |
| P/E Ratio | ★ $32.03 | $56.27 |
| Revenue Growth | ★ 11.75 | N/A |
| 52 Week Low | $67.42 | $6.69 |
| 52 Week High | $107.27 | $15.42 |
| Indicator | MMSI | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.41 | 34.89 |
| Support Level | N/A | $11.55 |
| Resistance Level | $84.91 | $12.85 |
| Average True Range (ATR) | 2.31 | 0.50 |
| MACD | -0.39 | -0.16 |
| Stochastic Oscillator | 7.26 | 21.61 |
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.